Gelucire 5013 Gattefosse

Gelucire 50/13 was provided by Gattefosse (Cedex, France) and has m.p.

Gelucire 5013 gattefosse. Gelucire ® 50/13, Gattefosse) may serve as both. Modulation of drug release. Sol id if yi ng an d emu ls if yi ng age nt s for.

As discussed previously, even though most Gelucires have T m > 37°C, (the most frequently used for SLN/NLC formulation up to now is Gelucire 50/13), their T m after processing to colloidal dimensions is expected to be decreased, leading to only partially crystallized lipid matrix. It is composed of fatty acid (majority of C 16 and C 18) esters of glycerol, PEG esters and free PEG. The formulation with labrafil or Gelucire® 50/02 are too lipophilic to give a good dissolution in water.

Several of these products listed are liquid or semi-solid, hence suitable for soft or hard shell capsules. Other products, such as. BAIJUDIER, PHILIPPE, SERVAIS, CECILIE, VANDERBIST, FRANCIS.

Solid state characterization, kinetic solubility, powder dissolution, stability, and pharmacokinetics were analyzed in rats. Application Water dispersible surfactant, Solubilizer, Bioavailability enhancer, Component of SELF, Matrix for modified release, Multiparticulates;. Mejoradores de la Biodisponibilidad.

Semi-solid bioavailability enhancer and sustained release agent. Solubilizer for poorly-soluble APIs and bioavailability enhancer. It melts at approximately 50°C and has hydrophilic-lipophilic balance (HLB) value of 13 6, 7.

Single excipient formulation system:. The excipient is primarily a mix-ture of PEG 1500 mono- and diesters with. Peceol ™ Labrafac ™ lipophile WL 1349;.

Lipid binder in melt processes. A number of systems were prepared at five compositions (5, 10, , 30 and 40% w/w) of diclofenac/N-(2-hydroxyethyl) pyrrolidine salt and acidic diclofenac in PEG6000 and Gelucire 50/13, as. Priority to BE priority Critical Application filed by Galephar M/F filed Critical Galephar M/F Priority to PCT/BE01/ priority patent/WOA1/en Assigned to GALEPHAR M/F reassignment GALEPHAR M/F ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).

Ranitidine HCl– lipid granules were prepared by the melt granulation technique and evaluated for in vitro floating and drug release. Gelucire® 50/13 is a well characterized excipient, supported by numerous publications and worldwide precedence of use including FDA IID listing. Self-emulsifies in aqueous fluid into coarse emulsion—LFCS Type III (SMEDDS).

R=C16 or C18 Schematic structures PEG1500 esters O H R -C O -O 3 3 O -C O -R R -C O -O 3 3 Phospholipon® 90G Phospholipon® 90G was received as a gift sample from Phospholipid GmbH (Nattermannalle, Germany). The aim of this study was to develop a formulation containing fenofibrate and Gelucire(®) 50/13 (Gattefossé, France) in order to improve the oral bioavailability of the drug. Tocopheryl propylene glycol succinate, Sucroester 15, Gelucire 50/13, and Myrj 52.

Gelucire® 44/14 is a versatile semi-solid lipidic excipient, proven to improve the bioavailability of poorly soluble drugs. Gelucire 50/13 (semi-synthetic polyglycolized glycerides) was provided by Gattefosse, St.Priest, Cedex, France. The average particle size of Gelucire 43/01 beads were not affected significantly by increasing Gelucire 43/01 ratio.

Precirol ® ATO 5 Vehículos Oleosos. Craig, The physical characterisation of. Gelucire ® 50/13 It is a non-ionic, water dispersible surfactant composed of well-characterized PEG-esters, a small glyceride fraction and free PEG.

Single excipient formulation system:. Self-emulsifies in aqueous media forming a fine dispersion, i.e., microemulsion (SMEDDS). Lauroglycol ™ FCC Y 90;.

All other materials and reagents used were of analytical grade. 50 °C and HLB 13. It is able to self-emulsify on contact with aqueous media forming a fine dispersion i.e.

Application of Acconon C-50® and Gelucire 50/13® as Both Solidifying and Emulsifying Agents for Medium Chain Triglycerides Journal of Excipients and Food. Gelucire ®50/13 (Stearoyl macrogol-32 glycerides) - bioavailability enhancement and sustained release Labrafil ®M2125 CS (Linoleyl macrogol-6 glycerides) - bioavailability enhancement Labrafil. A stability study on samples was conducted for 3 months to evaluate the physical state of the drug and its dissolution in the formulation.

Solubilizer for poorly-soluble APIs and bioavailability enhancer. People make our name. Application Water dispersible surfactant, Solubilizer, Bioavailability.

Its chemical name is Stearoyl macrogol-32 glycerides. This is a purified, de-oiled, and granulated soy lecithin with a high phosphatidylcholine. Functionality Solubilizer for poorly-soluble APIs and bioavailability enhancer.

The effect of variation in the Gelucire 50/13 concentration on the particle size of the Precirol SLN was also evaluated. The two numbers of Gelucires show their melting points and HLB values, respectively. Preparation of solid dispersions (SDs) and physical mixtures (PMs) Solubility enhancement of glibenclamide.

Gelucire® 50/13 was a gift by Gattefossè (Milan, Italy). It has similar surfactive properties to Gelucire® 44/14. One preferred BCS class II drug is TEL.

Gelucire® 44/14 has achieved official USP-NF status with pending Food Additive (FCC) status. One excipient that has stimulated interest in lipid-based solid dispersion formulations is Gelucire 44/14 (Gattefosse Corp., St. A mean particle size of approximately 250 nm was obtained for PVP K30-sirolimus nanoparticles.

Self-emulsifies in aqueous fluid. Self-emulsifies in aqueous fluid into coarse emulsion—LFCS Type III (SMEDDS). Particles from gas saturated solutions (PGSS) process was chosen for investigation as a manufacturing process for producing a ….

Single excipient formulation system:. US564B2 US13/525,857 USA US564B2 US 564 B2 US564 B2 US 564B2 US A US A US A US 564 B2 US564 B2 US 564B2 Authority US United States Prior art keywords isotretinoin pharmaceutical composition oral pharmaceutical composition mg Prior art date. The use of stearoyl macroglyceride (Gélucire® 50/13, Gattefosse) and soyabean oil allows to obtain a formulation with a dissolution profile similar to the reference (Roaccutane® mg, Roche).

Single excipient formulation system:. Application of Acconon C-50 and Gelucire 50/13 as Both Solidifying and Emulsifying Agents for Medium Chain Triglycerides. MATERIALS and METHODS Materials Bosentan was received as gift sample from MSN Pharma, India.

Gelucire® 44/14, Gelucire® 48/16, Gelucire® 50/13. Briefly, Precirol, 500 mg and Gelucire 50/13, at various concentrations (100, 150, 0, 250 and 650 mg) were transferred to a test tube. Solubilizer for poorly-soluble APIs and bioavailability enhancer.

Labrasol®, Gelucire® 44/14, Gelucire® 48/16, Gelucire® 50/13 and the Labrafil® series (Table 2) consist of self-emulsifying excipients that may be in SEDDS / SMEDDS. Different mixtures of the lipid and each solidifying agent were heated to 65ºC until homogenously mixed clear liquids were formed. All other materials and reagents were of analytical grade of purity.

Product description Gelucire® 50/13 (stearoyl polyoxyl-32 glycerides) is a nonionic water-dispersible surfactant for lipid-based formulations to solubilize and increase oral bioavailability of poorly water-soluble APIs. Solid self-emulsifying drug delivery systems (SEDDS) for medium chain triglycerides (Captex® 355, ABITEC) were developed using stearoyl polyoxyl glycerides (Acconon® C-50, ABITEC and Gelucire® 50/13, Gattefosse) as both solidifying and emulsifying agents. The average particle diameter of beads was found to be in the size range of 3.85 ± 0.13, 3.95 ± 0.21, and 3.87 ± 0.18 mm with varying drug/Gelucire 43/01 ratio from 1:5, 1:10, and 1:15, respectively (Table I).

However with a higher melting point and longer fatty acid chains it can have a release retarding effect when used at high concentration. Effect of variation in the Gelucire 50/13 concentration. This self-emulsifying excipient that exists as a waxy semi-solid at ambient room temperature is a mixture of glyceryl and PEG 1500 esters of long-chain fatty acids and is listed in the European Pharmacopoeia as laurylmacrogolglycerides and in the.

Lipid binder in melt processes. Development of Solid SEDDS, III:. Gelucire 50/13 is an excipient composed of fatty acid (C16 and C18) esters of glycerol, PEG esters and free PEG.

Dissolution studies were performed for melt granules of AET with Gelucire 50/13 (MG-AET) and solid dispersion with PVP (SDP) to differentiate dissolution performance. Between gelucire 50/13 and poloxamer 1 and to formulate the optimized solid dispersion into immediate release tablets. Gelucire ® 44/14 is a.

GELUCIRE 50/13 and GELUCIRE 53/10 can be used according to our invention, but GELUCIRE 50/13 has been found to be particularly effective. USB1 US09/623,213 USA USB1 US B1 US B1 US B1 US A US A US A US B1 US B1 US B1 Authority US United States Prior art keywords aqueous dispersion acid plasticizer lt dosage form Prior art date Legal status (The legal status is an assumption and is not a legal conclusion. Labrafil® series (Table 2) consist of self-emulsifying excipients that may be in SEDDS / SMEDDS.

This can be advantageous for certain drugs or peptides and in. Several of these products listed are liquid or semi-solid, hence suitable for soft or hard shell capsules. The results revealed that the moderate amount of Gelucire 43/01 and ethyl cellulose.

Legal notice - Terms and condition © Gattefossé People make our name. Legal notices - Terms and condition © Gattefossé People make our name. Self-emulsifies in aqueous fluid into coarse emulsion—LFCS Type III (SMEDDS).

Gelucire 33/01, 39/01 y 43/01… Capryol ™ PGM Y 90;. CA1 CAA CA CA1 CA A1 C A1 CA A1 CA A CA A CA A CA A C A CA A CA A1 C A1 CA A1 Authority CA Canada Prior art keywords isotretinoin pharmaceutical composition contains group consisting mixtures Prior art date Legal status (The legal status is an assumption. The dissolution of poorly water soluble drugs may be significantly enhanced in a solid dispersion with hydrophilic lipid excipients, such as Gelucire 50/13 (85), Gelucire 44/14 (,93) compared to.

Main components of Gelucire® 50/13. USB2 US11/2,363 USA USB2 US B2 US B2 US B2 US A US A US A US B2 US B2 US B2 Authority US United States Prior art keywords method isotretinoin composition group consisting selected Prior art date Legal status (The legal status is an assumption and is not a legal conclusion. Plurol Oleique ® CC497;.

Agente para enmascarar sabor. SAXS analysis of the untreated sample shows a lamellar phase of1Å(figure2).Nosignaloftheacylglycerol fraction was detected. Modulation of drug release.

Gelucire 50/13 was received as gift sample from Gattefosse, India, Poloxamer 1 was procured from Sigma Aldrich, India. Gelucire 50/13, and Gelucire 43/01 as lipid carriers. Journal of Excipients and Food Chemicals , S.l., v.

Mulations, Gelucire® 50/13—Controlled release and increased bio- availability , Gattefossé PF , first ed., April 99, 3000 ex, 1999. Gelucires 44/14 (lauroyl macroglycerides), 50/13 (stearoyl macroglycerides), 62/05 (glyceryl behenate), and Labrasol were supplied by Gattefossé (Saint-Priest cedex, France). Gelucire 39/01 y 43/01;.

Lipid binder in melt processes. Gelucire® 48/16, a novel carrier available in powder and pellet forms, is PEG-32 stearate, while, conventional gelucires, Gelucire® 44/14 and Gelucire® 50/13 are lauroyl polyoxyl-32glycerides NF and stearoyl polyoxyl-32 glycerides NF respectively. ABITEC) were developed using stearoyl polyoxyl glycerides (Acconon®C-50, ABITEC and Gelucire®50/13, Gattefosse) as both solidifying and emulsifying agents.